Zitvogel, Laurence

Custom scoring based on ecological topology of gut microbiota associated with cancer immunotherapy outcome

Derosa, L., Iebba, V., Silva, C. A. C., Piccinno, G., Wu, G., Lordello, L., Routy, B., Zhao, N., Thelemaque, C., Birebent, R., et al. (2024) · Cell

Gut microbiota and healthCancer Immunotherapy and Biomarkers

Cited by 198

Immunological Mechanisms Underneath the Efficacy of Cancer Therapy

Galluzzi, L., Zitvogel, L., & Kroemer, G. (2016) · Cancer Immunology Research

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 175

Intestinal microbiota influences clinical outcome and side effects of early breast cancer treatment

Terrisse, S., Derosa, L., Iebba, V., Ghiringhelli, F., Vaz-Luis, I., Kroemer, G., Fidelle, M., Christodoulidis, S., Segata, N., Thomas, A. M., et al. (2021) · Cell Death & Differentiation

Gut microbiota and healthCancer, Lipids, and Metabolism

Cited by 172

Microbiota-Centered Interventions: The Next Breakthrough in Immuno-Oncology?

Derosa, L., Routy, B., Desilets, A., Daillère, R., Terrisse, S., Kroemer, G., & Zitvogel, L. (2021) · Cancer Discovery

Gut microbiota and healthCancer Immunotherapy and Biomarkers

Cited by 170

Cyclophosphamide Induces Differentiation of Th17 Cells in Cancer Patients

Viaud, S., Flament, C., Zoubir, M., Pautier, P., LeCesne, A., Ribrag, V., Soria, J.-C., Marty, V., Vielh, P., Robert, C., et al. (2011) · Cancer Research

T-cell and B-cell ImmunologyPsoriasis: Treatment and Pathogenesis

Cited by 170

Oral administration of Akkermansia muciniphila elevates systemic antiaging and anticancer metabolites

Grajeda-Iglesias, C., Durand, S., Daillère, R., Iribarren, K., Lemaitre, F., Derosa, L., Aprahamian, F., Bossut, N., Nirmalathasan, N., Madeo, F., et al. (2021) · Aging

Gut microbiota and healthProbiotics and Fermented Foods

Cited by 161

Longitudinal gut microbiome changes in immune checkpoint blockade-treated advanced melanoma

Björk, J. R., Bolte, L. A., Maltez Thomas, A., Lee, K. A., Rossi, N., Wind, T. T., Smit, L. M., Armanini, F., Asnicar, F., Blanco-Miguez, A., et al. (2024) · Nature Medicine

Gut microbiota and healthCancer Immunotherapy and Biomarkers

Cited by 156

The breakthrough of the microbiota

Kroemer, G., & Zitvogel, L. (2018) · Nature Reviews Immunology

Gut microbiota and healthCancer Immunotherapy and Biomarkers

Cited by 147

Immunological off-target effects of imatinib

Zitvogel, L., Rusakiewicz, S., Routy, B., Ayyoub, M., & Kroemer, G. (2016) · Nature Reviews Clinical Oncology

Chronic Myeloid Leukemia TreatmentsGastrointestinal Tumor Research and Treatment

Cited by 142

Gut OncoMicrobiome Signatures (GOMS) as next-generation biomarkers for cancer immunotherapy

Thomas, A. M., Fidelle, M., Routy, B., Kroemer, G., Wargo, J. A., Segata, N., & Zitvogel, L. (2023) · Nature Reviews Clinical Oncology

Gut microbiota and healthCancer Immunotherapy and Biomarkers

Cited by 141

Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer

Buqué, A., Bloy, N., Perez-Lanzón, M., Iribarren, K., Humeau, J., Pol, J. G., Levesque, S., Mondragon, L., Yamazaki, T., Sato, A., et al. (2020) · Nature Communications

Cancer Immunotherapy and BiomarkersBreast Cancer Treatment Studies

Cited by 138

Gut microbiome and anticancer immune response: really hot Sh*t!

Viaud, S., Daillère, R., Boneca, I. G., Lepage, P., Langella, P., Chamaillard, M., Pittet, M. J., Ghiringhelli, F., Trinchieri, G., Goldszmid, R., et al. (2015) · Cell Death & Differentiation

Gut microbiota and healthCancer Immunotherapy and Biomarkers

Cited by 123

The presence of LC3B puncta and HMGB1 expression in malignant cells correlate with the immune infiltrate in breast cancer

Ladoire, S., Enot, D., Senovilla, L., Ghiringhelli, F., Poirier-Colame, V., Chaba, K., Semeraro, M., Chaix, M., Penault-Llorca, F., Arnould, L., et al. (2016) · Autophagy

Cancer Immunotherapy and BiomarkersAutophagy in Disease and Therapy

Cited by 117

Cancer Induces a Stress Ileopathy Depending on β-Adrenergic Receptors and Promoting Dysbiosis that Contributes to Carcinogenesis

Yonekura, S., Terrisse, S., Alves Costa Silva, C., Lafarge, A., Iebba, V., Ferrere, G., Goubet, A.-G., Fahrner, J.-E., Lahmar, I., Ueda, K., et al. (2022) · Cancer Discovery

Gut microbiota and healthGastrointestinal motility and disorders

Cited by 112

Natural killer cells are essential for the ability of BRAF inhibitors to control BRAFV600E-mutant metastatic melanoma

Ferrari de Andrade, L., Ngiow, S. F., Stannard, K., Rusakiewicz, S., Kalimutho, M., Khanna, K. K., Tey, S.-K., Takeda, K., Zitvogel, L., Martinet, L., et al. (2014) · Cancer Research

Melanoma and MAPK PathwaysImmune Cell Function and Interaction

Cited by 105

Immune-dependent antineoplastic effects of cisplatin plus pyridoxine in non-small-cell lung cancer

Aranda, F., Bloy, N., Pesquet, J., Petit, B., Chaba, K., Sauvat, A., Kepp, O., Khadra, N., Enot, D., Pfirschke, C., et al. (2015) · Oncogene

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 89

Melanoma and microbiota: Current understanding and future directions

Routy, B., Jackson, T., Mählmann, L., Baumgartner, C. K., Blaser, M., Byrd, A., Corvaia, N., Couts, K., Davar, D., Derosa, L., et al. (2024) · Cancer Cell

Gut microbiota and healthCancer Immunotherapy and Biomarkers

Cited by 89

A synergistic triad of chemotherapy, immune checkpoint inhibitors, and caloric restriction mimetics eradicates tumors in mice

Lévesque, S., Le Naour, J., Pietrocola, F., Paillet, J., Kremer, M., Castoldi, F., Baracco, E. E., Wang, Y., Vacchelli, E., Stoll, G., et al. (2019) · OncoImmunology

Cancer Immunotherapy and BiomarkersDietary Effects on Health

Cited by 86

Escherichia coli –Specific CXCL13-Producing TFH Are Associated with Clinical Efficacy of Neoadjuvant PD-1 Blockade against Muscle-Invasive Bladder Cancer

Goubet, A.-G., Lordello, L., Alves Costa Silva, C., Peguillet, I., Gazzano, M., Mbogning-Fonkou, M. D., Thelemaque, C., Lebacle, C., Thibault, C., Audenet, F., et al. (2022) · Cancer Discovery

Cancer Immunotherapy and BiomarkersBladder and Urothelial Cancer Treatments

Cited by 86

Can we harness the microbiota to enhance the efficacy of cancer immunotherapy?

Finlay, B. B., Goldszmid, R., Honda, K., Trinchieri, G., Wargo, J., & Zitvogel, L. (2020) · Nature Reviews Immunology

Cancer Immunotherapy and BiomarkersGut microbiota and health

Cited by 81

Immune system and intestinal microbiota determine efficacy of androgen deprivation therapy against prostate cancer

Terrisse, S., Goubet, A.-G., Ueda, K., Thomas, A. M., Quiniou, V., Thelemaque, C., Dunsmore, G., Clave, E., Gamat-Huber, M., Yonekura, S., et al. (2022) · Journal for ImmunoTherapy of Cancer

Prostate Cancer Treatment and ResearchGut microbiota and health

Cited by 80

Faecalibacterium prausnitzii strain EXL01 boosts efficacy of immune checkpoint inhibitors

Bredon, M., Danne, C., Pham, H. P., Ruffié, P., Bessede, A., Rolhion, N., Creusot, L., Brot, L., Alonso, I., Langella, P., et al. (2024) · OncoImmunology

Cancer Immunotherapy and BiomarkersGut microbiota and health

Cited by 74

The intestinal microbiota determines the clinical efficacy of immune checkpoint blockers targeting PD-1/PD-L1

Derosa, L., Routy, B., Kroemer, G., & Zitvogel, L. (2018) · OncoImmunology

Cancer Immunotherapy and BiomarkersGut microbiota and health

Cited by 74

Trial watch: immune checkpoint blockers for cancer therapy

Vanpouille-Box, C., Lhuillier, C., Bezu, L., Aranda, F., Yamazaki, T., Kepp, O., Fucikova, J., Spisek, R., Demaria, S., Formenti, S. C., et al. (2017) · OncoImmunology

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 73